FHIR IG analytics| Package | us.nlm.vsac |
| Resource Type | ValueSet |
| Id | ValueSet-2.16.840.1.113762.1.4.1259.9.json |
| FHIR Version | R4 |
| Source | https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1259.9/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.9 |
| Version | 20230817 |
| Status | active |
| Date | 2023-08-17T01:00:54-04:00 |
| Name | IgEAgonistsPrescribable |
| Title | IgE Agonists, prescribable |
| Realm | us |
| Authority | hl7 |
| Purpose | (Clinical Focus: The purpose of this value set is to represent concepts for IgE Agonists appropriate for asthma control.),(Data Element Scope: This value set may be used to represent a Medication.),(Inclusion Criteria: Includes concepts that describe a medication specific to prescribable SBD/SCD TTYs for Omalizumab.),(Exclusion Criteria: None) |
No resources found
| CodeSystem | |
| rxnorm | RxNorm |
No narrative content found in resource
{
"resourceType": "ValueSet",
"id": "2.16.840.1.113762.1.4.1259.9",
"meta": {
"versionId": "5",
"lastUpdated": "2023-12-21T17:43:03.000-05:00",
"profile": [
"http://hl7.org/fhir/StructureDefinition/shareablevalueset",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
]
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
"valueContactDetail": {
"name": "One Medical Author"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
"valueDate": "2024-05-06"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
"valueDate": "2023-08-17"
}
],
"url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.9",
"identifier": [
{
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113762.1.4.1259.9"
}
],
"version": "20230817",
"name": "IgEAgonistsPrescribable",
"title": "IgE Agonists, prescribable",
"status": "active",
"date": "2023-08-17T01:00:54-04:00",
"publisher": "One Medical Steward",
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "US"
}
]
}
],
"purpose": "(Clinical Focus: The purpose of this value set is to represent concepts for IgE Agonists appropriate for asthma control.),(Data Element Scope: This value set may be used to represent a Medication.),(Inclusion Criteria: Includes concepts that describe a medication specific to prescribable SBD/SCD TTYs for Omalizumab.),(Exclusion Criteria: None)",
"compose": {
"include": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"concept": [
{
"code": "1657209",
"display": "omalizumab 150 MG Injection"
},
{
"code": "1657212",
"display": "omalizumab 150 MG Injection [Xolair]"
}
]
}
]
},
"expansion": {
"identifier": "urn:uuid:0f71b7a4-9c8e-4cd9-8cb6-01760bc6ab26",
"timestamp": "2025-05-23T21:01:32-04:00",
"total": 2,
"contains": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657209",
"display": "omalizumab 150 MG Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657212",
"display": "omalizumab 150 MG Injection [Xolair]"
}
]
}
}